Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
Nina Shah, MD, touched on important abstracts being presented at the 2021 American Society of Hematology Annual Meeting.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: There are a lot of interesting abstracts being presented at this year’s upcoming American Society of Hematology Annual Meeting. A lot of them have to do with relapsed or refractory disease. We’re going to get longer follow-up on [ciltacabtagene autoleucel] for duration of response or progression-free survival. We’re also going to learn a lot more about the bispecific T-cell engagers. Most of these have been in phase 1 [trials] with expansion cohorts, but now we have longer follow-up for some of the later molecules that have come through. Teclistamab has had the longest follow-up that we know of, but there are other molecules that are being studied and presented, and we’re going to have a better idea of those agents in the BCMA [B-cell maturation anitgen] space.
In the non-BCMA space, we’ll get longer follow-up data on things like talquetamab [JNJ-64407564], as well as cevostamab [BFCR4350A]. That’s very important for considering patients who may be having BCMA failures. In addition, there’s going to data on quality of life, and I’m excited to see that because it’s important. That’s the other outcome that we need to look at, not just response, duration of response, and PFS, but how are people feeling because if we’re doing a good job making them live longer, we certainly want them to live a happier life as well.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
